These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

FluMist, which was initially approved in 2023, is indicated for individuals from two to 49 years old. Those who want to ...

Yahoo Life reached out to FluMist’s manufacturer, AstraZeneca, to ask when the product might be available for at-home use but ...

1 Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: “The approval of FLUMIST for self-administration is an important step forward in making vaccines more ...

The US Food and Drug Administration (FDA) has approved the first self-administered seasonal influenza vaccine - AstraZeneca’s FluMist. FluMist has been available in the US since 2003 ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

AstraZeneca has said it has "no idea" where ... around 400 people and is dedicated primarily to the production of AZ's FluMist vaccine for influenza. When the plan was first announced by the ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN) has received approval from the US Food and Drug Administration (FDA) for its FluMist influenza vaccine to be self-administered, marking a significant shift in ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first ...

(Alliance News) - AstraZeneca PLC on Friday announced that its influenza vaccine FluMist has been approved for self-administration in the US. The Cambridge, England-based biopharmaceutical company ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.